Investigation of Secreted Phosphoproteins and PiP3 (Phosphoinositolphospat 3) in Sputum
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03076086|
Recruitment Status : Completed
First Posted : March 9, 2017
Last Update Posted : February 1, 2018
|Condition or disease||Intervention/treatment||Phase|
|Healthy Smoking, Cigarette||Other: Induced sputum procedure||Not Applicable|
Within the study, sputum samples will be collected at 3 repetitive occasions in a 3 week interval of the different donors.
The objective is to assess for biomarker specificity and reproducibility in the two groups (smokers and non-smokers). The methods for measurement shall be validated by repetitive measurement of the sputum samples, i.e. comparison of multiple measurements of the same sample and comparison of different samples from the same donor.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Investigation of Secreted Phosphoproteins and PiP3 (Phosphoinositolphospat 3) in Sputum Samples of Healthy Smokers and Non Smokers|
|Actual Study Start Date :||May 12, 2017|
|Actual Primary Completion Date :||January 15, 2018|
|Actual Study Completion Date :||January 15, 2018|
Experimental: induced sputum procedure
Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors.
Other: Induced sputum procedure
induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
- Biomarker assessment [ Time Frame: up to 3 weeks ]concentration of PiP3 and phosphoproteins in sputum samples
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03076086
|Hannover, Niedersachsen, Germany, 30625|
|Principal Investigator:||Jens Hohlfeld, MD||Fraunhofer-Institute of Toxicology and Experimental Medicine|